EE200100046A - ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks - Google Patents

ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks

Info

Publication number
EE200100046A
EE200100046A EEP200100046A EEP200100046A EE200100046A EE 200100046 A EE200100046 A EE 200100046A EE P200100046 A EEP200100046 A EE P200100046A EE P200100046 A EEP200100046 A EE P200100046A EE 200100046 A EE200100046 A EE 200100046A
Authority
EE
Estonia
Prior art keywords
acat
administration
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
EEP200100046A
Other languages
English (en)
Estonian (et)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200100046A publication Critical patent/EE200100046A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
EEP200100046A 1998-07-21 1999-06-18 ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks EE200100046A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
EE200100046A true EE200100046A (et) 2002-06-17

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100046A EE200100046A (et) 1998-07-21 1999-06-18 ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks

Country Status (25)

Country Link
EP (1) EP1098662A2 (is)
JP (1) JP2002521328A (is)
KR (1) KR20010083134A (is)
CN (1) CN1310629A (is)
AP (1) AP2001002035A0 (is)
AU (1) AU4701799A (is)
BG (1) BG105162A (is)
BR (1) BR9912296A (is)
CA (1) CA2335062A1 (is)
CZ (1) CZ2001126A3 (is)
EA (1) EA200100153A1 (is)
EE (1) EE200100046A (is)
HR (1) HRP20010055A2 (is)
HU (1) HUP0102880A3 (is)
ID (1) ID30030A (is)
IL (1) IL140982A0 (is)
IS (1) IS5809A (is)
NO (1) NO20010291L (is)
OA (1) OA11584A (is)
PL (1) PL346011A1 (is)
SK (1) SK502001A3 (is)
TR (1) TR200100205T2 (is)
WO (1) WO2000004892A2 (is)
YU (1) YU3501A (is)
ZA (1) ZA200100294B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
AU2003267991B2 (en) * 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
ATE207891T1 (de) * 1996-05-17 2001-11-15 Warner Lambert Co Biphenylsulfonamid matrix metalloproteinase inhibitoren
KR20000068414A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도

Also Published As

Publication number Publication date
CZ2001126A3 (cs) 2002-01-16
HRP20010055A2 (en) 2002-04-30
ID30030A (id) 2001-11-01
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
HUP0102880A2 (en) 2002-06-29
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A2 (en) 2000-02-03
WO2000004892A3 (en) 2000-05-18
ZA200100294B (en) 2002-01-10
AU4701799A (en) 2000-02-14
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
HUP0102880A3 (en) 2002-11-28
NO20010291L (no) 2001-01-18
CN1310629A (zh) 2001-08-29
EP1098662A2 (en) 2001-05-16
IS5809A (is) 2001-01-12
EA200100153A1 (ru) 2001-08-27
YU3501A (sh) 2005-06-10
AP2001002035A0 (en) 2001-03-31
TR200100205T2 (tr) 2001-05-21
PL346011A1 (en) 2002-01-14
KR20010083134A (ko) 2001-08-31
SK502001A3 (en) 2002-06-04
BG105162A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
CY2018023I1 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
ID22957A (id) Senyawa dan penggunaannya
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
PT977748E (pt) Derivados benzopirano substituidos para o tratamento de inflamacao
DK1070069T3 (da) Bicycliske hydroxaminsyrederivater
ID27394A (id) Kombinasi farmasi yang mengandung inhibitor cox-2 dan inhibitor inos
DE59908110D1 (de) Cas-erfassbarer endoskop-adapter
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
EE200100243A (et) 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks
PT1077940E (pt) 4-fenilpiperidinas novas para o tratamento de dermatoses pruriginosas
ID29943A (id) Senyawa dds dan metode pengukurannya
FI962904A7 (fi) Metalloproteinaasi-inhibiittoreita
PT1206436E (pt) Retinoides para o tratamento de enfisema
NO20010291D0 (no) Coadministrasjon av ACAT og MMP inhibitorer for behandling av aterosklerotiske sår
IT1301973B1 (it) Idro-fluoroalchilvinileteri e procedimento per il loro ottenimento
IT1302811B1 (it) Procedimento e relativo apparato per la riduzione direttadi ossidi di ferro
PT1079818E (pt) Composicao compreendendo il-18 e topotecano para o tratamento e /ou prevencao de cancro
IT1296305B1 (it) Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ID28797A (id) Tioredoksin dan pemrosesan biji-bijian
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc